Precision Neuroscience Inc. recently partnered with Beth Israel Deaconess Medical Center to test its brain computer interface, the Layer 7 Cortical Interface, during craniotomy procedures.
Guillain-Barré syndrome (GBS) is an immune-driven inflammatory disorder of the peripheral nervous system characterized by muscle weakness and paralysis. Despite treatment options, GBS stays severe, with a mortality rate of 3%-10%. The mechanisms behind GBS are poorly understood and new therapeutic options are needed.
Aminoglycoside antibiotics are essential for treating some severe bacterial infections but are notorious for causing irreversible hearing loss in 20%-47% of patients.
The new gene therapy aims to address the root cause of prion disease by using the CHARM epigenetic editing platform from the Whitehead Institute to target and silence the gene that codes for the disease-causing protein.
Shenzhen Hightide Biotechnology Ltd. has divulged prodrugs and derivatives of 2,4-dinitro phenol reported to be useful for the treatment of obesity, diabetes, liver disease, heart disease, renal failure, neurodegenerative diseases and aging, among others.
After Study 1’s independent data monitoring committee said the experiment will likely fall short of its primary endpoint with ulixacaltamide in essential tremor, Praxis Precision Medicines Inc. plans to wait for full data from Study 1 as well as Study 2 in the Essential 3 phase III program before deciding on regulatory moves.
The EMA’s Committee for Medicinal products for Human Use (CHMP) is standing by its opinion on Leqembi (lecanemab) after the European .mission pushed back against a recommendation in November 2024 that the Alzheimer’s disease drug be approved
NLS Pharmaceutics Ltd., in collaboration with Aexon Labs Inc., has announced new preclinical findings on AEX-2, a non-sulfonamide dual orexin receptor agonist (DOXA) with potential for narcolepsy and related neurological disorders.
The FKBP5 gene encodes FKBP prolyl isomerase 5, a co-chaperone that modulates glucocorticoid signaling and that is expressed in T cells, neurons and in microglial cells in the central nervous system (CNS). The role of FKBP5 in the dysregulation of myeloid cells in the pathogenesis of multiple sclerosis was investigated in a murine model of experimental autoimmune encephalomyelitis.
Shanghai Pharmaceuticals Holding Co. Ltd. has disclosed aza-ergoline derivatives acting as dopamine D2 receptor and/or D3 receptor agonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), depression, erectile dysfunction, substance abuse and dependence, restless legs syndrome, schizophrenia, Parkinson’s and Alzheimer’s disease, among others.
RSS
